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Abdominal free flaps for microsurgical breast reconstruction are most commonly harvested based on the deep inferior epigastric
vessels that supply skin and fat via perforators through the rectus muscle and sheath. Intact perforator anatomy and connections
are vital for subsequent optimal flap perfusion and avoidance of necrosis, be it partial or total. The intraflap vessels are delicate and
easily damaged and it is generally advised that patients should avoid heparin injection into the abdominal pannus preoperatively
as this may compromise the vascular perforators through direct needle laceration, pressure from bruising, haematoma formation,
or perforator thrombosis secondary to external compression.We report three cases of successful deep inferior epigastric perforator
(DIEP) flap harvest despite patients injecting therapeutic doses of low molecular weight heparin into their abdomens for
thrombosed central venous lines (portacaths) used for administering primary chemotherapy in breast cancer.
1. Introduction
Deep inferior epigastric vessels provide the basis for the
commonest abdominal free flaps used for breast reconstruc-
tion. Arising from the external iliac vessels, they supply the
infraumbilical skin and fat via perforators through the rectus
muscle and sheath. Perforator vascular anatomy of the DIEP
flap has been well studied, with Saint-Cyr et al. [1–3] elucidat-
ing the spatial organisation of the perforating vessels and their
delicate intraflap branches. Intact perforator anatomy and
horizontal connections are vital for optimal flap perfusion [1–
5]. Patients are therefore advised to avoid any preoperative
interventions that may damage the perforators and their
branches and thus compromise flap perfusion. The latter
includes injecting prophylactic or therapeutic low molecular
weight heparin (LMWH) into the anterior abdominal fat.
We have previously reported on the safety of perform-
ing abdominal free flap operations following neoadjuvant
chemotherapy [6] even when this is complicated by central
venous catheter thrombosis [7]. The incidence of thrombosis
in implanted central venous catheters in oncology patients
undergoing long-term chemotherapy is 6.4–7.3% [8, 9]. This
is treated by anticoagulation, which may be delivered by
instillation, flushing, or systemic administration [10, 11]. In
some patients, however, line-related thrombosis propagates
and leads to symptomatic occlusion of the subclavian or
innominate veins and/or pulmonary embolization [7]. These
patients are normally managed by therapeutic anticoagula-
tion for at least 3months, using daily subcutaneous injections
of the LMWH, which are continued until the line is removed
[12].Themost accessible injection site is the lower abdominal
pannus, the very tissue needed for DIEP flap breast recon-
struction. There has been no previous study on the effects of
LWMH administration into the abdominal pannus on subse-
quent flap harvest and perfusion.
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We report three cases of successful DIEP flap transfer
for immediate breast reconstruction despite injections of
therapeutic doses of enoxaparin into their abdominal fat 24–
32 hours beforemicrosurgical transfer. All three patients were
treated by primary chemotherapy for breast cancer and were
prescribed subcutaneous heparin for line-related throm-
botic complications. They were referred for reconstructive
consultations towards the end of their chemotherapy and
had already been receiving subcutaneous injections into the
abdominal fat when a decision regarding DIEP flap recon-
struction was taken.
2. Case Reports
2.1. Patient 1. A 55-year-old female with multifocal grade III
invasive carcinoma of the left breast had her right subcla-
vian vein cannulated for primary chemotherapy. Six weeks
later, she developed a left axillary vein thrombus and was
commenced on 1.5mg/kg (100mg) enoxaparin once daily.
This was self-administered subcutaneously into the lower
abdomen. Following chemotherapy, she underwent a mas-
tectomy and DIEP flap reconstruction. On the day prior to
surgery, therapeutic enoxaparin was omitted having been last
administered 32 hours before her operation. No bruising was
visible immediately preoperatively. There were no bleeding
problems intraoperatively and estimated blood loss was
800mL. She was commenced on a prophylactic dose of
enoxaparin (40mg daily) for the duration of her admission
starting 6 hours after surgery. She also required a 3-unit blood
transfusion. Her total breast and abdominal drain output was
2.7 L of serosanguineous fluid during her 7-day hospital stay.
There were no flap circulatory or bleeding problems at the
donor or recipient sites.
2.2. Patient 2. A 33-year-old female with grade III invasive
ductal cancer was treated by primary chemotherapy to be
followed by bilateral mastectomy (therapeutic on one side
and prophylactic on the other side) along with bilateral
DIEP flap reconstructions. Due to a history of port-related
thromboses 13 years previously during treatment for ovarian
cancer, shewas put on prophylactic 40mgdaily subcutaneous
enoxaparin.Theheparinwas injected into the lower abdomen
above the groin creases and bilateral thighs whilst she had a
femoral Groshong line for chemotherapy (Figure 1). A preop-
erative abdominal wall CT scan performed 48 hours before
surgery (Figure 2) showed subcutaneous opacities consistent
with bruising in the lower abdomen, particularly on the left
side. The dose was reduced to 0.1mg/kg (10mg) in the two
weeks prior to surgery and stopped the day before her surgery
where an estimated 700mL of bloodwas lost. Postoperatively,
she received two units of blood and took 5,000 units of dal-
teparin daily for twoweeks as thromboprophylaxis. Her drain
output whilst in hospital is shown in Table 1. Both flaps were
successful and there were no bleeding problems.
2.3. Patient 3. A 37-year-old female with a grade II invasive
ductal carcinoma developed a left subclavian port-related
thrombosis one month after the start of 6 cycles of primary
chemotherapy and was started on a course of therapeutic
Figure 1: Preoperative photograph of a 33-year-old female (Patient
2) showing skin bruising on the left lower abdomen prior to bilateral
mastectomy and DIEP flap reconstruction.
Figure 2: Preoperative CT angiogram of Patient 2 demonstrating
subcutaneous opacities, representing subcutaneous bleeding from
heparin injection over the left abdomen. Note the close proximity
to DIEP perforators.
enoxaparin at 1mg/kg (80mg) daily, administered subcu-
taneously into her lower abdomen. Anticoagulation was
stopped 32 hours before mastectomy and DIEP flap recon-
struction. Preoperative photographs (Figure 3) demonstrated
bruises in the lower abdomen that correlated with her CT
scan findings 1 month prior to surgery of bilateral opacities
consistent with soft tissue injury reported as representing
bruising or inflammation of the subcutaneous fat (Figure 4).
Intraoperative blood loss was estimated at 560mL and she
did not require a blood transfusion. Postoperatively, she was
given 5,000 units of dalteparin subcutaneously daily for 6
days, before being discharged. Her flap remained healthy and
healed well with no complications.
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Table 1: Table of clinical data.
Patient 1 2 3
Age (years) 55 33 37
BMI (kg/m2) 25 40 29
Tumour Grade III III II
Receptor status ER+/HER2− ER-/HER2− ER+/HER2+
Reason for anticoagulation Axillary vein thrombosis History of port-related thrombosis Subclavian vein thrombosis
Time to thrombus 6 weeks NA 4 weeks
Enoxaparin dose (mg) 100 40 80
Duration of anticoagulation 3 months 2 months 4 months
Time LMWH stopped preoperatively (hours) 32 h 24 h (10mg, 2 weeks earlier) 32 h
Operation side Unilateral Bilateral Unilateral
Lymph node surgery Level II ANC Level II ANC SLNBx
Flap weight (grams) 662 g 794 g (L), 805 g (R) 690 g
Perforators Lateral row ×4 Medial row ×1 (L), lateral row ×2 (R) Medial row ×1
Ischaemia time (mins) 97 79 (L), 80 (R) 26
EBL from swab weights (mL) 800 719 560
Thromboprophylaxis 40mg enoxaparin 5000 units of dalteparin 5000 units of dalteparin
Total drain output (litres) 2.7 L 1.2 L 1.2 L
Hospital stay 7 days 7 days 6 days
EBL: estimated blood loss.
NA: not applicable.
ANC: axillary node clearance.
SLNBx: sentinel lymph node biopsy.
Figure 3: Preoperative photograph of a 37-year-old female (Patient
3) showing bilateral lower abdominal skin bruising at the sites
of heparin injection prior to right mastectomy and DIEP flap
reconstruction.
3. Discussion and Conclusion
Although there are currently no formal guidelines on the
administration site of anticoagulants prior to free flap har-
vest, it is generally thought that administration of LMWH
may damage the vasculature through local haemotoxic and
mechanical effects. This could threaten flap viability, as
quality and reliability of perfusion are partially dependent on
intact subdermal plexus and direct or indirect linking vessel
patency [1, 3, 4]. It is equally important to try to avoid com-
promise to alternative nonintended perforators, just in case a
rescue vessel is required.
We report three cases of successful abdominal free flap
transfer for immediate breast reconstruction surgery after
administration of subcutaneous heparin doses into the lower
Figure 4: CT angiogram of Patient 3 showingmultiple small subcu-
taneous haemorrhages bilaterally at the sites of heparin injections.
DIEP branches appear intact in adjacent fat. The inferior epigastric
arteries are seen running posterior to the rectus muscle and sheath.
abdomen. In all cases, the last dose was administered
approximately 32–36 hours prior to surgery, with none given
on the evening before the operation. At prophylactic doses
of subcutaneous heparin, there is no difference in bruising
or APTT when using alternate injection sites on the thigh
[13, 14] and upper arm [13] instead of the abdomen. However,
the upper thigh should be avoided since the subfascial plane
is a potential space which can allow haemorrhagic spread to
the retroperitoneal space [15] and injections to the upper arm
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greatly inconvenience everyday activities. The anterior
abdominal wall remains the site of choice for subcutaneous
injections. We recommend that patients who may be
potential candidates for DIEP flap reconstruction and their
physicians should be educated on exact flap harvest location.
Subcutaneous injections should be restricted to at least 5 cm
above the umbilicus to avoid inadvertent damage to the flap
perforatorswhich are located in the infraumbilical abdominal
pannus.
There has been a previous report of flap success despite
accidental subcutaneous injection of low dose enoxaparin
immediately adjacent to the perforators [16]. The authors
commented that this was inappropriate and could have
resulted in flap failure. Our cases extend the literature and
confirm that local intraflap LMWH administration should
not be considered an absolute contraindication for free flap
harvest. If injections have been administered in the flap
area, preoperative CT angiography [17] should be used to
confirm the integrity of the intraflap vasculature prior to free
tissue transfer. Despite clinically and radiologically evident
bruising, while there is a theoretical risk of fat necrosis should
perfusion be compromised, we have not experienced this in
our clinical practice and estimate the probability of this to
be low. To confirm the viability of the perforators selected
for intraoperative use on CT angiography, we recommend
the adjunctive use of a handheld Doppler probe immediately
preoperatively. Importantly, it is also now our practice to
advise patients to avoid injecting proximal to potential lower
abdominal donor sites once a decision for DIEP flap harvest
has been made and if local areas on one side appear bruised
on clinical examination we consider using the vessels on
the contralateral side, albeit keeping in mind the optimal
perforator anatomy delineated by CT angiography.
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